Because many COVID-19 vaccines are designed to train the immune system to recognize features of the virus, changes in those features can affect how well existing antibodies recognize a new variant.
A variant that is better able to evade some existing antibodies may be more capable of causing infections in people who have been vaccinated or previously infected. This phenomenon is often described as immune evasion.
Immune evasion does not mean the virus has become completely invisible to the immune system. Protection is not an all-or-nothing process. Antibodies may recognize a new variant less efficiently, while other immune responses continue to provide some defense against serious disease.
Vaccine formulations may also be updated as the virus evolves. The aim is to improve the match between the immune response generated by vaccination and the variants expected to circulate.
This is similar in principle to updating other preventive tools when the conditions they must address change. A vaccine developed for an earlier viral version may not provide exactly the same level of protection against a newer version, particularly against infection. Nevertheless, existing immune responses can remain valuable.
3. Exposure can influence the outcome
A person's risk of becoming infected is also affected by the circumstances of exposure.
Spending a brief period outdoors with good airflow is not the same as spending several hours in a crowded indoor room where an infected person is coughing. Close contact, poor ventilation, prolonged exposure, and the presence of an infectious person can all influence the likelihood of transmission.
Vaccination reduces certain risks, but it does not eliminate the need to consider exposure. When the virus is circulating widely, even people with some immune protection may encounter it.
This helps explain why infections sometimes occur in households, workplaces, healthcare facilities, and other settings where people spend extended periods close together. A vaccinated individual may have a lower risk of certain outcomes but can still be exposed to a sufficient amount of virus to become infected.
It is also important not to interpret infection as proof that a person behaved irresponsibly. Exposure is not always avoidable, and people cannot reliably identify every infectious person they encounter.
The purpose of prevention is to reduce risk where possible, not to imply that every infection reflects a personal failure.
4. People do not all develop the same immune response
Even when two people receive the same vaccine, their immune responses may differ.
Age is one factor. The immune system changes throughout life, and older adults may respond differently to vaccination than younger adults. Some people also have conditions or receive treatments that weaken immune function.
For example, certain cancer treatments, organ-transplant medications, and other immunosuppressive therapies can interfere with the body's ability to develop or maintain a strong response. People living with particular chronic conditions may also face a higher risk of severe illness if they become infected.
The US Centers for Disease Control and Prevention identifies older adults, people with certain medical conditions, people with weakened immune systems, and pregnant women among groups that can face increased risk from severe respiratory illness. Individual risk depends on the person's circumstances.
These differences matter when interpreting breakthrough infections. A person whose immune response is weakened may have less protection than another person who received the same vaccine. That does not mean vaccination has no value for people with weakened immune systems; rather, it means their protection and preventive needs may require individual assessment by a healthcare professional.
5. Previous infection and vaccination create different layers of immunity
Some people have been vaccinated but never had COVID-19. Others have experienced one or more infections before or after vaccination. Their immune histories are not identical.
Immunity developed through vaccination and immunity developed after infection can both contribute to the body's ability to recognize SARS-CoV-2. When a person has both, the resulting protection is often called hybrid immunity.
The strength and duration of that protection vary, and neither previous infection nor vaccination guarantees that a person will never become infected again. Infection itself can also lead to complications, including prolonged symptoms, so deliberately seeking infection is not a safe substitute for prevention.
The WHO notes that hybrid immunity can provide stronger protection against severe outcomes from future infections than infection alone. It also advises that people follow the vaccination recommendations of their national programmes, particularly when they belong to groups at elevated risk.
These layers of immunity help explain why two people exposed to the same variant may have different outcomes. One may have recent vaccination, a previous infection, or both; another may have more distant immune exposure. Age, health, and the intensity of exposure add further differences.
What Breakthrough Infection Really Means
The term breakthrough infection can sound alarming, especially when it appears in a headline. It simply describes an infection that occurs despite vaccination. The term does not automatically indicate that the illness is severe, that the vaccine has stopped working, or that the person will transmit the virus for a particular length of time.
A breakthrough infection can be asymptomatic, mildly symptomatic, or serious. Its outcome depends on many factors, including the person's immune status, age, medical history, the virus involved, and the time since their last vaccination or infection.
The term also covers different situations that should not be confused with one another. A vaccinated person who tests positive without symptoms and a vaccinated person who requires hospital care both have breakthrough infections, but the clinical consequences are very different.
That is why the frequency of breakthrough infections alone is not a complete measure of vaccine performance. Researchers need to consider how often infections lead to severe disease and how those outcomes compare across appropriate groups.
A useful way to think about vaccine effectiveness is to separate several questions:
-
Does vaccination reduce the likelihood of becoming infected?
-
Does it reduce the likelihood of developing symptomatic illness?
-
Does it reduce the likelihood of hospitalization?
-
Does it reduce the likelihood of critical illness or death?
-
Does protection change with time, age, health status, or viral variant?
The answer to one question does not automatically determine the answer to the others.
Evidence reviewed by the WHO indicates that COVID-19 vaccines continue to provide protection against severe disease and death, even though they do not prevent every infection. A 2026 systematic review and meta-analysis also reported that vaccination reduced the risk of progression from symptomatic infection to hospitalization, while noting variation across age groups, study definitions, and variant periods.
The practical message is not that breakthrough infections should be ignored. They are important for public-health surveillance and for understanding how the virus changes. Rather, they should be interpreted in context.
If infections occur after vaccination, researchers need to ask whether the frequency and severity of those infections differ from what would be expected without vaccination. A single case cannot answer that question, and a headline describing one infection cannot substitute for population-level evidence.
Can Vaccinated People Still Spread COVID-19 to Others?
Yes. A person who has been vaccinated can still transmit SARS-CoV-2 if they become infected. Vaccination should therefore not be understood as a guarantee that someone cannot pass the virus to family members, coworkers, or other people.
However, transmission is not determined by vaccination status alone. It can be influenced by the amount of virus present, the stage of infection, the circulating variant, the person's immune response, and the nature of their contact with others.
Some vaccinated people who develop COVID-19 may have a shorter period of detectable infectious virus or lower levels of virus than comparable unvaccinated people, but these patterns are not universal. The degree of protection against infection and transmission can also change as immunity wanes and new variants emerge.